Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 31 Advanced Solid Tumors 25 Advanced Solid Tumor 24 Carcinoma, Non-Small-Cell Lung 19 Neoplasms 15 Solid Tumor 12 Prostatic Neoplasms 12 Multiple Myeloma 11 Pancreatic Neoplasms 10 Neoplasm Metastasis 10 Small Cell Lung Carcinoma 9 Recurrence 9 Ovarian Neoplasms 9 Lung Neoplasms 9 Stomach Neoplasms 8 Melanoma 8 Lymphoma, Large B-Cell, Diffuse 8 Leukemia, Myeloid, Acute 8 Carcinoma, Hepatocellular 8 Triple Negative Breast Neoplasms 7 Sarcoma 7 Colorectal Neoplasms 7 Uterine Cervical Neoplasms 6 Solid Tumors 6 Carcinoma, Transitional Cell 5 Advanced Solid Tumour 5 Squamous Cell Carcinoma of Head and Neck 4 Nasopharyngeal Carcinoma 4 Myelodysplastic Syndromes 4 Lymphoma 4

Interventions

SH-1028 1 Injections 1 2-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-5-(2-hydroxy-3-morpholinopropyl)-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo(3,2-c)azepin-4-ketone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Solid Cancer × Injections × Clear all

NCT07265921 2025-12-05

Solid Tumors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Recruiting

Advanced Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡